Among a group of women who had reached midlife, the persistent chemicals known as PFAS appeared in a quiet pattern alongside slightly thinner muscle, though not in a way that weakened strength or movement. The women, followed since before their children were born, offered a window onto a question that matters as the body moves through menopause and muscle naturally begins to wane. Yet the evidence captures only a moment, so it shows an echo rather than a cause, leaving open whether these substances quietly shape the slow erosion of strength or whether other currents, such as body size, carry t
'Forever Chemicals' Linked to Slightly Lower Muscle Mass in Midlife Women, Not Function
Slightly lower muscle mass, without corresponding evidence of poorer muscle function
Mark
So what did the study actually find?
Mimi
Women with higher blood levels of certain PFAS, notably PFUnDA, PFDA and PFNA, had slightly lower muscle mass in midlife. The six-chemical mixture showed it most clearly.
Mark
But the women weren't weaker?
Mimi
Right. Grip strength showed no link, and some women with higher PFDA or PFOA actually scored slightly better on the physical performance battery.
Luke
Worth saying why that may not be reassuring or alarming. Most participants hit the top score, so that test may not detect small differences.
Mark
Does this show PFAS cause muscle loss?
Luke
No. Exposure and muscle mass were measured at about the same time. The authors say so directly.
Mimi
And when they adjusted for prepregnancy body mass index, the inverse associations weakened, so body size may explain part of it.
Mark
The burden score and the mixture analysis disagreed, didn't they?
Luke
Yes. The burden score was weak and uncertain; the six-PFAS mixture was clearer. I wouldn't lean hard on either one.
Mark
Who were these women?
Mimi
Mostly college-educated, non-Hispanic White, relatively healthy, all had given birth. That narrows who the results speak for.
Luke
And the menopause question is still open. Some associations looked stronger after menopause, but the difference wasn't statistically clear.
Il Polso
- Several long-lived PFAS compounds in midlife blood track with slightly lower limb muscle mass in women around menopause.
- The signal weakens when body size is accounted for, leaving researchers unsure how much of the pattern is chemical and how much is simply frame.
- Grip strength and physical performance show no steady link, and most participants hit the test's maximum score, blunting any difference that might exist.
- Mixture analyses pull in different directions, with one approach offering a clearer hint of lower muscle at higher combined exposure and another offering only a faint, uncertain trace.
- Because blood and muscle were measured at the same moment, the story cannot yet tell whether chemicals drive muscle loss; longitudinal tracking over years is the next step to settle it.
Among a group of women who had reached midlife, the persistent chemicals known as PFAS appeared in a quiet pattern alongside slightly thinner muscle, though not in a way that weakened strength or movement. The women, followed since before their children were born, offered a window onto a question that matters as the body moves through menopause and muscle naturally begins to wane. Yet the evidence captures only a moment, so it shows an echo rather than a cause, leaving open whether these substances quietly shape the slow erosion of strength or whether other currents, such as body size, carry the weight instead.
A group of 551 women, average age 50.7, returned for a midlife visit as part of Project Viva, a long-running Massachusetts study that had first welcomed them at prenatal appointments between 1999 and 2002. Researchers drew their blood, scanned the lean tissue in their limbs, and tested their grip and physical performance. The central question was whether PFAS, the so-called forever chemicals that linger in bodies and environments for years, follow the muscle changes that arrive around menopause.
The team, drawn from institutions including Tufts, Harvard, Stanford, the CDC, and Columbia, was filling a gap. Earlier work hinted that PFAS can stir inflammation and dampen testosterone, both connected to muscle decline, and postmenopausal women face high rates of sarcopenia and falls. Yet no prior study had looked closely at this exposure around menopause and muscle health together.
The findings are suggestive but tangled. Higher midlife levels of PFUnDA, PFDA, and PFNA were each linked to slightly lower muscle mass. Combined-exposure analyses told a less tidy story: one showed a weak, uncertain tie, while another found a clearer, modest association at higher overall levels. Strength and performance, however, did not follow the same path. Some women with higher exposures even scored slightly better on the physical battery, and grip strength showed no consistent link. Most participants hit the test's maximum score, which may have hidden small differences. Adjusting for body size weakened the associations, a reminder that frame and composition may be doing much of the talking.
The authors are clear about what this cannot tell us. Exposure and muscle were measured at the same time, so the study reveals a correlation, not a mechanism. The women were mostly college-educated, healthy, and had all given birth, which limits how far the results reach. What comes next is patience: following women over years to see whether PFAS exposure precedes muscle loss, and how much it matters beside better-understood influences like activity and nutrition.
A group of 551 women, average age 50.7, came in for a midlife visit as part of Project Viva, a long-running study in Massachusetts that first enrolled them at prenatal appointments between 1999 and 2002. Researchers drew blood, measured the lean tissue in their limbs with dual-energy X-ray absorptiometry, and tested their grip strength and physical performance. The question was whether the persistent chemicals known as PFAS, the so-called forever chemicals, track with muscle health around menopause.
The work, published in Environmental Epidemiology, came from researchers at MaineHealth Institute for Research, Tufts University School of Medicine, Harvard Medical School, Stanford University, the US Centers for Disease Control and Prevention, and Columbia University Mailman School of Public Health. They were filling a gap. Earlier studies suggest PFAS can raise inflammatory cytokines and lower testosterone, changes tied to loss of muscle mass and function. Higher PFAS exposure has also been linked to greater fat mass and poorer bone health in adults. Yet the authors say no previous work had examined PFAS exposure around menopause and muscle health, even though postmenopausal women have higher rates of sarcopenia and falls than men.
The main measure was appendicular lean mass index, or ALMI, which adjusts limb lean mass for height as an estimate of skeletal muscle mass. Muscle function was secondary: handgrip strength and the Short Physical Performance Battery, scored to a maximum of 12. Researchers treated lower scores as less-than-optimal performance, not necessarily clinical impairment. Models accounted for age, education, race and ethnicity, household income, months of breastfeeding, lifetime births, and menopausal status. The team also analyzed PFAS in combination, using a burden score from the PFAS Exposure Burden Calculator and a six-chemical mixture analyzed with quantile g-computation.
Not every woman contributed to every analysis: 488 were included in the muscle mass analysis, 545 in grip strength, and 273 in physical performance testing. Most were college graduates (79%), non-Hispanic White (67%), and postmenopausal (59%). On average they had 2.5 births and had breastfed for 21.3 months. PFOS was the most abundant chemical in midlife blood, with a geometric mean of 2.58 ng/mL, followed by PFOA at 1.44 ng/mL. PFHxS, PFOA, and PFOS levels were lower in midlife than during pregnancy. Average ALMI was 6.93 kg/m², average grip strength was 28.1 kg-force, and about 26% scored below 12 on the performance battery.
Higher midlife levels of PFUnDA, PFDA, and PFNA were each associated with lower ALMI. The mixture results were less tidy. The burden score showed a weak, uncertain link to lower muscle mass, while the six-chemical analysis found a clearer association with slightly lower muscle mass at higher combined exposure.
Function told a different story. Women with higher PFDA, PFOA, or burden scores were actually less likely to score below 12 on the performance battery, a slightly better result, and there was no association with grip strength. Because most participants hit the maximum score, the test may have been unable to pick up small differences. Pregnancy data added further ambiguity: higher PFOS during pregnancy was associated with higher midlife ALMI, while pregnancy PFNA showed an uncertain inverse association.
The researchers found no consistent evidence that the PFAS-muscle mass link varied by physical activity, menopausal status, or diet. Some associations looked stronger after menopause, but the differences between groups were not statistically clear. Adjusting for prepregnancy body mass index weakened the inverse associations, suggesting body size may partly explain what was seen.
The authors stress limits. Exposure and muscle mass were measured at roughly the same time, so the main analyses cannot show whether PFAS contributed to muscle loss, and unmeasured factors such as body composition may have played a role. All participants had given birth and most were relatively healthy, which may limit relevance for older or more diverse groups. The authors call for longitudinal studies to test whether PFAS exposure leads to muscle loss over time, and how it compares with established, modifiable influences on muscle health.
Citazioni salienti
The main analyses measured exposure and muscle mass at about the same time, so they cannot establish whether PFAS contributed to muscle loss.— Study authors, Environmental Epidemiology (paraphrased)
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗